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Summary
Targeting of oncogenic driver mutations with small-mo-
lecule inhibitors resulted in powerful treatment options for
cancer patients in recent years. The RAS (rat sarcoma)
pathway is among the most frequently mutated pathways
in human cancer. Whereas targeting mutant Kirsten RAS
(KRAS) remains difficult, mutant B rapidly accelerated
fibrosarcoma (BRAF) kinase is an established drug target
in cancer. Now data show that neuroblastoma RAS
(NRAS) and even Harvey RAS (HRAS) mutations could
be predictive markers for treatment with mitogen-activated
protein kinase (MEK) inhibitors. This review discusses re-
cent preclinical and clinical studies of MEK inhibitors in
BRAF and RAS mutant cancer.
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RAS signalling pathway
RAS (rat sarcoma) kinases are evolutionarily conserved
kinases that are important within the
RAS–RAF–MEK–ERK pathway. Up to now, three mem-
bers have been identified: neuroblastoma RAS (NRAS),
Harvey RAS (HRAS), and Kirsten RAS (KRAS). The RAS
family of small GTPases is stimulated either by upstream
receptors or activating mutations. Upon activation, RAS
changes its form from the inactive (GDP-bound) to the act-
ive (GTP-bound) form [1]. This process is regulated by
guanine nucleotide exchange factors (GEFs) that favour
the GDP to GTP exchange. The resulting conformational
change leads to binding to rapidly accelerated fibrosarcoma
(RAF) kinase, the first kinase downstream of RAS, and
subsequent RAF dimerisation. Different forms of RAF
kinases are known: ARAF, BRAF and CRAF (RAF-1).
Activated RAF phosphorylates and activates the down-
stream kinase mitogen-activated protein kinase kinase
(MEK), which in turn phosphorylates and activates the
extracellular signal-regulated kinase (ERK) [1]. Phos-
phorylated ERK can translocate to the nucleus where it
phosphorylates and activates various transcription factors.
These include members of the ETS (E26 transformation-
specific) family of transcription factors such as ELK1,
which stimulates FOS expression. Further, ERK phos-
phorylates c-JUN leading to the formation of heterodimers
of c-JUN and FOS. These heterodimers enable the ex-
pression of cell cycle proteins such as cyclines [2]. The
RAS–RAF–MEK–ERK pathway has also been shown to
activate other effector pathways like the phosphatidylinos-
itol 3-kinase (PI3K) pathway [3]. Mutant RAS in particu-
lar was shown to activate the PI3K/mammalian target of
rapamycin (mTOR) signalling [3]. Whether the PI3K path-
way alone or in combination with the RAS pathway would
provide a promising target for cancer therapy is currently
under preclinical and early preclinical investigation [4].
The RAS–RAF–MEK–ERK pathway can be inactivated
at level of the RAS kinases. Inactivation is secured by
GTPase-activating proteins (GAPs) which lead to GTP hy-
drolysis and, thus, shift conformation to the inactive GDP-
bound form [5]. This inactivation process is the target for
mutations found in cancers. RAS mutations commonly oc-
cur at residues G12 and G13, which prevent binding
between RAS and GAP and finally prevent hydrolysis of
GTP [5]. Mutations at Q61 interfere with GTP hydrolysis
directly by disturbing the orientation of a water molecule
needed for hydrolysis. The consequence of these mutations
is that the RAS kinase is kept in its active state, leading to
continuous activation of the subsequent downstream effect-
ors, which is often referred to as hyperactivation.
Common mutations in the RAS
pathway
First, NRAS mutations were discovered in 1983 on chro-
mosome 1 of neuroblastoma tumors; this was then fol-
lowed by identification of KRAS and HRAS [6]. NRAS,
HRAS and KRAS are mutated to a very different frequency
depending on tissue background (table 1). KRAS mutations
are predominantly found in pancreatic cancer (57%), in
small and large intestinal cancers (34% and 23%, respect-
ively) and lung cancer (17%) [7]. Interestingly, almost all
mutations for pancreatic, colon, and lung cancer do occur
at position G12 and very rarely at position G13 or Q61 (7).
NRAS mutations are often found in melanomas (11%) and
tumours of the haematopoietic and lymphoid system
(10%). Nearly all mutations of NRAS in melanoma are
found at position Q61, whereas in haematopoietic and
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 9
lymphoid tumours the mutations are distributed between
G12, G13 and Q61 [7].
HRAS mutations are predominantly found in bladder can-
cer (9%), upper digestive tract (6%), and skin and cervix
cancer (16% and 5%, respectively) (table 1) [7]. Whereas
HRAS mutations in cervix cancer are predominantly found
at G12, bladder, skin and upper digestive tract cancers
show a more diverse pattern.
Of note, mutations of BRAF, KRAS, and NRAS are usu-
ally mutually exclusive whereas mutations of the PI3K
pathway may overlap with mutations in BRAF, KRAS, and
NRAS [8].
The reason for the varying distribution of NRAS, HRAS
and KRAS mutations between different cancer types and
the complex pattern of hotspot mutations is not well under-
stood so far. Some in-vitro and preclinical data show that
one RAS mutation might substitute for another, whereas
other studies report the opposite. These studies will be fur-
ther discussed in the following paragraph.
In a carcinogen-induced mouse tumour model, it was
demonstrated that HRAS can fully substitute for KRAS
Q61L, indicating that both have comparable capacity to
promote tumour growth [9]. The authors also found that
specificity of KRAS mutations for lung cancer or HRAS
mutations for skin cancer is dependent on regulatory ele-
ments of the corresponding gene [9]. This shows that
tissue-specific regulated expression and tissue-specific reg-
ulatory elements might be the reason if KRAS, NRAS or
HRAS are undergoing mutations. However, in a colon can-
cer mouse model, only KRAS G12D, but not NRAS G12D,
stimulated proliferation of colonic epithelial cells [10]. In
addition, another study in a tumour mouse model observed
that NRAS G12D could not equal the aggressive myelo-
proliferative disorder caused by the KRAS G12D muta-
tion [11]. Although NRAS G12D mice ultimately died of
haematological cancers, they did not develop as aggress-
ive a course of leukaemic disease as KRAS G12D mice
did [11]. A recent publication showed that only the NRAS
Q61R mutation had the potency to generate melanomas
and activate downstream signalling, whereas the NRAS
G12D mutation did not [12]. This finding might explain the
predominance of NRAS Q61 mutations over other onco-
genic NRAS mutations in human melanoma. Taken togeth-
er, the oncogenic potential of NRAS, HRAS and KRAS
and the respective sites of the mutation might vary among
the different isoforms and could be dependent on the tissue
context.
This conclusion is supported by the following example of
targeting mutant BRAF. BRAF mutations can be found in
melanoma (43%), papillary thyroid cancer (41%), colon
cancer (13%) and haematological malignancies such as
Langerhans cell histiocytosis (57%) (table 1) [7, 13].
BRAF V600E is a remarkable target for BRAF inhibitors
in melanoma patients, with response rates of about 50%
[14]. Early clinical data of BRAF V600E in lung cancer
also indicate successful treatment options, but less strong
than those seen for BRAF mutant melanoma. However,
preclinical data from colon cancer shows that BRAF in-
hibitors alone are not sufficient to block tumour growth
and require combination therapy with upstream epidermal
growth factor receptor (EGFR) antibodies in cell culture
and xenograft models [15, 16]. These data demonstrate that
BRAF V600E is a promising target; however, the efficacy
of BRAF inhibitors very much depends on tissue type and
the respective signalling. In conclusion, it should be taken
into consideration that the various mutations and their po-
tential as drug targets should be investigated separately.
This should include the form of mutant RAS involved, the
position of the mutation, tissue lineage and maybe even
subgroups thereof.
Table 1: Frequency of mutations in HRAS, KRAS, NRAS, and BRAF in different cancers. Data accessed from the Catalogue of somatic mutations in cancer (COSMIC) [7].
Disease KRAS NRAS HRAS BRAF
Biliary tract 31% (1679) 1% (287) 0% (153) 5.3% (982)
Bone 1% (252) 0% (207) 2% (199) 7.9% (716)
Breast 4% (782) 2% (504) 1% (716) 1.1% (3836)
Brain 1% (1054) 1% (1017) 0% (964) 8% (490)
Cervix 7% (1009) 2% (132) 5% (527) 9.9% (802)
Endometrium 14% (2251) 0% (4544) 1% (291) 0% (4544)
Haematopeotic and lymphoid tissue 5% (5978) 9% (15226) 0% (3076) 10% (8671)
Kidney 1% (704) 0% (435) 0% (273) 0% (7339)
Large Intestine 34% (53826) 0% (2211) 0% (671) 13% (9391)
Lung 17% (4742) 0.6% (12053) 0.5% (4031) 2.2% (14682)
Oesophagus 4% (375) 0% (161) 1% (161) 0.5% (1517)
Ovary 12% (5653) 5% (191) 0% (152) 7.1% (4476)
Pancreas 57% (8691) 0.6% (1838) 0.2% (1459) 2% (2308)
Pleura 3% (169) 3% (77) 0% (1551) 2% (197)
Prostate 4% (2210) 2% (588) 2% (1457) 1.4% (1981)
Salivary Gland 2% (402) 0.7% (276) 9% (401) 1% (322)
Skin 2.3% (3729) 11% (508) 16% (10377) 43% (9048)
Small Intestine 23% (656) 0% (232) 1% (132) 4% (413)
Stomach 6% (281) 2% (215) 4% (384) 1% (262)
Testis 3.4% (146) 3% (283) 2.2% (356) 2.4% (325)
Thymus 2% (261) 0% (46) 0% (49) 0% (53)
Thyroid 2% (7717) 7% (7154) 7% (7154) 41% (19449)
Upper aerodigestive tract 2% (3845) 1.4% (2.40) 6% (153) 0.9% (2671)
Urinary tract 4% (1953) 2% (873) 9% (2914) 2% (1124)
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Blocking the RAS pathway by rapidly
accelerated fibrosarcoma (RAF)
kinase inhibitors
The first attempts to block hyperactivated RAS signalling
in cancer were to address directly mutant RAS. Unfortu-
nately, these attempts remained unsuccessful, as described
below.
Since RAS has a very high affinity to GTP, in the picomolar
range, inhibition of nucleotide binding is more challenging
than with the ATP-binding pockets of other kinases. Anoth-
er way of targeting RAS activation is to prevent RAS bind-
ing to the cell membrane, which is crucial for RAS activa-
tion. RAS is modified post-translationally by farnesylation,
which allows binding to the cell membrane. Direct target-
ing of mutant RAS by farnesylation inhibitors was encour-
aging in preclinical studies, but did not show any bene-
fit in clinical studies with unselected patient populations
[17, 18]. Despite these failures, RAS as a drug target was
not abandoned. In 2013, the National Institutes of Health
(NIH) launched the RAS initiative, a multidisciplinary ef-
fort, including the biotechnology and pharmaceutical in-
dustries, to explore novel strategies to treat RAS-driven tu-
mours.
So far, the most effective way to target RAS signalling in
cancer is with RAF inhibitors. However, this possibility
exists only if the BRAF downstream of RAS is mutated
and activated. BRAF is most commonly mutated in melan-
oma, where the V600E mutations seem to be the predomin-
ant mutation [7]. Specific inhibitors for BRAF V600E like
vemurafenib (Zelboraf®; Genentech/Plexxikon) or dabraf-
enib (Tafinlar®; GSK) proved to be clinically successful
with response rates of 50%, significant progression-free
survival and overall survival in patients with metastatic
melanoma [14, 19]. These were impressive results after
decades without therapies having an effect on overall sur-
vival. However, as anticipated, the responses were termin-
ated by occurrence of resistant mutations such as an activ-
ating mutation in NRAS, MEK1 or AKT and appearance of
a BRAF V600E splice variant, which favour RAF dimer-
isation [20]. Currently, phase III clinical trials have demon-
strated that combination of the BRAF and MEK inhibitors
could further improve clinical responses, which will be dis-
cussed below [21, 22].
Blocking RAS signalling with mitogen-
activated protein kinase (MEK)
inhibitors
Instead of inhibiting RAS, downstream MEK represents
another opportunity as drug target. Interestingly, in a large
phase III clinical study it was found that MEK inhibition
alone is effective in BRAF V600E-positive melanoma pa-
tients [23]. The MEK inhibitor trametinib showed a better
outcome for response rate, progression-free survival and
overall survival than standard chemotherapy [23]. Al-
though a head-to-head trial of a MEK inhibitor versus a
BRAF inhibitor is lacking, the clinical efficacy of trametin-
ib compared with vemurafenib (or dabrafenib) seems equal
in BRAF mutant melanoma patients. This is in line with
very early preclinical studies showing that BRAF mutant
cell lines are highly sensitive to either RAF or MEK inhib-
ition [24]. Therefore, sufficient preclinical and clinical data
are available to target MEK in RAF mutated cancers. MEK
is an interesting and promising target for small molecule
inhibitors. MEK has a specific pocket structure, which is
close to the MgATP-binding site. This pocket structure is
conserved among MEK proteins and represents an ideal
target for allosteric inhibitors [25]. After binding of a MEK
inhibitor, conformational changes keep the unphos-
phorylated MEK in a nonfunctional state [26]. Since bind-
ing of the MEK inhibitor does not interfere with ATP bind-
ing to the active kinase site, MEK inhibitors are highly spe-
cific to MEK kinases at very low nanomolar concentrations
and have fewer off targets than other inhibitors [25]. Sever-
al compounds that show very potent inhibitory activity of
MEK1/2 are currently in clinical development or even ap-
proved (fig. 1). Whereas nonspecific binding of MEK in-
hibitors might not contribute to toxities, animal studies in
MEK1/2 knock-out in mice led to perinatal death, showing
that MEK activity is required in adult animals [27]. This
indicates that MEK inhibitors may have specific toxicities,
which will be discussed later.
Approved MEK inhibitors and MEK
inhibitors in advanced clinical studies
Cobimetinib (GDC-0973, XL-518, Cotellic®)
Cobimetinib is the first MEK inhibitor approved by Swiss-
medic in Switzerland [28]. It is approved for treatment of
BRAF V600 mutant metastatic melanoma in combination
with vemurafenib (Zelboraf®). The approval of Swissmed-
ic came even before the approval by the US Food and
Drug Administration (FDA), which was approved by FDA
in November 2015. Approval was based on the phase III
Figure 1
Schematic representation of the RAS signalling pathway. RAS
activates both the MAPK and the PI3K/mTOR pathways
downstream. Inhibitors for both pathways are shown. Vemurafenib,
dabrafenib and cobimetinib are approved in Switzerland, whereas
others are mostly in early and some in advanced clinical
development.
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CoBRIM trial with 495 patients and its recent update [29,
30]. Patients received 960 mg vemurafenib twice daily for
28 days in combination with either placebo or 60 mg cobi-
metinib once a day from days 1 to 21 (in a 28-day cycle)
(29). In the follow up report, the overall response rate
was 70% for the combination versus 50% for vemurafen-
ib alone [30]. Progression-free survival was significantly
higher for the combination at 12.3 versus 7.2 months
whereas median overall survival was not reached yet [30].
Risk for death seemed to be significantly lower in the com-
bination arm. Cobimetinib showed an acceptable safety
profile but grade 3 and 4 events were reported for 63% of
patients in the combination group and 58% in the vemuraf-
enib arm [30]. The majority of adverse events included
diarrhoea, nausea, rash, arthralgia, fatique and increased
creatine phosphokinase levels (higher in the combination
arm). As expected, keratoacanthomas and cutaneous
squamous-cell carcinoma were significantly less frequent
in the combination arm [30]. In conclusion, the combin-
ation of vermurafenib and cobimetinib represents a novel
treatment option for BRAF mutant melanoma patients in
Switzerland.
As discussed for other MEK inhibitors in this review, re-
sponses in early clinical trials were observed mostly ex-
clusively in patients with mutations in the RAS pathway. In
a phase I study, for example, treatment with cobimetinib in-
duced 3 partial responses among the 46 patients with vari-
ous advanced solid tumors. The 3 partial responses were
observed in patients with BRAF mutant melanoma, BRAF
mutant pancreatic cancer and in a KRAS-mutant endo-
metrial cancer [31]. This demonstrates the importance of
a selected patient population based on mutations and other
biomarkers for successful outcome of clinical trials.
Trametinib (GSK1120212, Mekinist®)
Trametinib first showed clinical activity in a phase I study
including 206 patients with pancreas cancer, colorectal
cancer and melanoma [32]. In unselected populations, 2
pancreas cancer patients out of 21 showed a partial re-
sponse and 2 out of 26 patients with NSCLC had a partial
response [32]. The most sensitive population had BRAF
mutant and NRAS mutant melanoma patients, with a re-
sponse rate of 33%, demonstrating the importance of
highly selected populations [32].
Thus, trametinib was further studied in BRAF mutant
melanoma. In patients with metastatic melanoma harbour-
ing a BRAF V600E/K mutation, single-agent trametinib
compared with dacarbazine showed significantly longer
progression-free survival of 4.8 months in the trametinib
group compared with 1.5 months in the standard chemo-
therapy group [23]. Based on these results trametinib was
approved by the FDA in 2013, and by the European Medi-
cines Agency (EMA) in 2014. Trametinib has not been ap-
proved by Swissmedic.
Combinations of trametinib and dabrafenib were found to
be even more effective. Progression-free survival and over-
all response rate were higher for the combination of tramet-
inib and dabrafenib in metastatic melanoma, which led to
approval of the combination therapy by the FDA in 2014
[30]. These findings were supported by more mature data
from a phase III study. The combination of trametinib and
dabrafenib increased median overall survival by 6 months
[21, 22]. Thus, two different combinations of BRAF and
MEK inhibitors have by now been shown to induce clinic-
ally meaningfull responses.
Selumetinib (AZD6244)
Selumetinib is another prominent example of a clinically
successful MEK inhibitor. Though selumetinib is not ap-
proved yet, the FDA has granted it orphan drug status for
the treatment of uveal melanoma. Phase III data are expec-
ted by the end of this year. Further, selumetinib is being in-
vestigated in phase III studies in KRAS mutant lung cancer
and thyroid cancer.
In preclinical studies, selumetinib effectively blocked cell
growth of melanoma and hepatocellular cell lines in cell
culture and in in-vivo models [34, 35]. Selumetinib de-
creased ERK phosphorylation in tumour cell lines and also
in 80% of tumour biopsies in a phase I study [36]. Clinical
activity was first demonstrated with three cases of pro-
longed stable disease in patients with medullary thyroid
cancer or uveal melanoma or renal cancer (one case each)
[36]. In addition, several phase II studies proved the effic-
acy of single-agent selumetinib. Selumetinib caused par-
tial remission in 3 (12%) and stable disease in 14 (50%)
of 28 patients with metastatic biliary cancers, whereas no
response was detected in papillary thyroid carcinoma or
hepatocellular carcinoma [37]. In an unselected population
of melanoma patients, selumetinib and temozolomid had
comparable response rates of 10% [38]. Of note, patients
responding to selumetinib showed a BRAF mutation in five
out of six cases [38]. In a study focusing on BRAF mutated
melanoma, 3 of 15 patients had partial responses [39].
However, inhibition of MEK did not result in a clinical re-
sponse in acute myeloid leukaemia, which might be ow-
ing to greater heterogeneity of the disease [40]. Further-
more, single-agent selumetinib did not demonstrate superi-
ority over temozolomide in melanoma, over pemetrexed in
NSCLC, over capecitabine in pancreatic cancer and over
capecitabine in colorectal cancer.
Interestingly, selumetinib has been extensively studied in
combination treatments with other drugs. One recent early
trial investigated the combined effect of selumetinib with
the AKT inhibitor MK2206. Twenty-nine patients with
various KRAS mutant cancers were included; 3 of 13
(23%) patients with NSCLC had a partial response as did
one of two (50%) patients with ovarian cancer [41]. One of
the NSCLC patients had a durable) response for 15 months
[41]. This, again, nicely demonstrates the importance of
carefully selecting patient populations on the basis of his-
tology and molecular biomarkers.
The combination of selumetinib and cetuximab showed
promising first results in a phase I study with solid tumours
including KRAS mutated colorectal cancer [42]. Two pa-
tients with partial responses and two with with stable dis-
ease out of 13 patients were observed in patients with
KRAS mutated colorectal cancer and one stable disease in
a patient with tonsillar squamous cell carcinoma and one
with NSCLC [42].
Several combinations of selumetinib with vandetanib,
cixutumumab, docetaxel, gemcitabine, and irinotecan are
currently being tested in clinical trials.
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MEK inhibitors in early clinical
development
CI-1040/PD-0325901
CI-1040 was the first MEK inhibitor which made it to clin-
ical trials but did not produce an objective response in
an unselected population of 67 patients including NSCLC,
breast, colon and pancreatic cancers [43]. Its predecessor
PD-0325901 has excellent oral bioavailability and has
higher potency to block MEK1/2. However, PD-0325901
caused unacceptable side effects, such as retinal vein oc-
clusion, and clinical development was stopped. Currently,
only two clinical studies aim to investigate PD-0325901 in
combination with (1) a CDK4/6 inhibitor in KRAS mutant
NSCLC and (2) an endothelial growth factor receptor
(EGFR) inhibitor in KRAS mutant colon cancer (clinical-
trials.gov).
Pimasertib (AS703026, MSC1936369B)
The efficacy of pimasertib was studied in a phase I study
of patients with advanced solid tumours including melan-
oma and colorectal cancer [44]. As seen with other MEK
inhibitors, pimasertib caused tumour shrinkage mostly in
patients with BRAF or NRAS mutations. Now it is being
studied in a phase II study of pimasertib versus dacarbazine
in patients with NRAS mutated metastatic melanoma. In a
setting of 88 KRAS mutated pancreatic cancer patients, pi-
masertib did not improve overall response rate or overall
survival in combination with gemcitabine versus gemcit-
abine alone [45]. The finding suggests that KRAS muta-
tions alone are not a sufficient predictive marker for treat-
ment with MEK inhibitors (see molecular markers for KEK
inhibitors, below). Combination of pimasertib with
5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in
KRAS-mutated metastatic colorectal cancer showed high
toxicity and is therefore not a treatment option [46]. Sever-
al combination studies of pimasertib with the PI3K/mTOR
inhibitor SAR245409, or with the mTOR inhibitor temsir-
olimus, or with gemcitabine are ongoing.
Refametinib (BAY 86-9766, RDEA119)
Refametinib is under early clinical investigation with only
one partial response in 53 unselected patients with various
cancers [47]. The one responding patient had colorectal
cancer and was considered “wild-type” according to RAS
and PI3K mutation status [47]. Of note, two BRAF mutant
melanoma patients showed progression on refametinib.
The combination of refametinib with sorafenib led to par-
tial response in three and stable diseases in 25 of 69 Asian
patients with hepatocellular carcinoma [48]. However, tox-
icity was high, with four grade 5 treatment-related adverse
events and dose modifications for all patients. Combination
studies of refametinib with gemcitabine in patients with
metastatic pancreatic cancer and with the PI3K inhibitor
BAY80-6946 are ongoing.
More MEK inhibitors under clinical evaluation
Several MEK inhibitors are currently under early clinical
evaluation including AZD8330 (ARRY-424704),
RO4987655 (CH4987655), WX-554, E6201, and
TAK-733. Further, RO5126766, which is a novel dual
RAF/MEK inhibitor, is also currently investigated in phase
I clinical trials.
Toxicity of MEK inhibitors
Most toxicity from MEK inhibitors observed so far in-
cludes unspecific events that are common to most small-
molecule kinase inhibitors. These toxicities include rash,
fatigue and diarrhoea [26]. However, ocular toxicities are
specific to MEK inhibitors and occur as blurred and re-
duced vision. Retinal vein occlusion stopped development
of PD-0325901, but has not been observed with other in-
hibitors of MEK. More commonly described is central ser-
ous retinopathy [26]. Toxicities are temporary and can be
reversed by reduction of dose or drug interruption. Side
effects with low impact on patients’ status are periorbital
oedema and elevation of creatine phosphokinase. Overall,
toxicities from MEK inhibitors are similar to toxicities
known from other small-molecule inhibitors and readily
manageable.
Resistance to MEK inhibitors
Cobimetinib and trametinib are the only MEK inhibitors
approved so far. Trametinib and cobimetinib are mostly
used in combination with BRAF inhibitors and rarely as
single agent. Thus, knowledge gained on resistance is
based on combined therapy and for a limited number of pa-
tients. Despite impressive clinical efficacy and few reports
of long-term responding patients, half of patients under
combined combination treatment ultimately relapse, after
about 10 months. Whereas acquired resistance to BRAF in-
hibitors is driven by activating alterations in the RAS path-
way (MAPK activation, increased BRAF copy numbers,
altered splicing of BRAF, mutations in NRAS or MEK1/2
or upregulation of other receptor tyrosine kinases), it was
commonly believed that mechanisms independent of the
RAS pathway would occur [49]. Surprisingly, a study from
last year identified MEK2 Q60P and MEK2 C125S muta-
tions, BRAF amplification and BRAF splice variants as
resistance mechanism for combined treatment of BRAF
and MEK inhibitors [49, 50]. This show that resistance
arises within the RAS pathway, which renders it more dif-
ficult to overcome resistance. How to best treat patients
with tumour progression on MEK inhibitors (in combina-
tion with RAF inhibitors) is currently unknown. One group
which investigated the MEK2 Q60P mutation found that
resistant cells could be resensitised by a triple combination
of dabrafenib, trametinib, and a PI3K/mTOR inhibitor [51].
Hence, resistance might require novel combination ther-
apies to overcome it.
Molecular markers for MEK inhibitors
The RAS pathway is a prominent example of successful
targeted therapy. BRAF mutations are a strong predictive
marker for treatment with BRAF inhibitors in clinical stud-
ies, as described above. Nonmutant BRAF tumours are not
responding to BRAF inhibitors in preclinical studies, on the
contrary; tumours even grow as a result of a paradoxical ac-
tivation of the RAS pathway [52, 53]. RAS mutations are,
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however, not yet established and whether KRAS, NRAS
and HRAS mutation can be used as reliable predictive pos-
itive markers for MEK inhibitors is currently under invest-
igation and will be discussed in the next paragraphs.
KRAS mutation is a poor predictive marker for single
MEK inhibitor treatment
Based on preclinical and early clinical studies, KRAS
seems to be a poor predictive marker for response to MEK
inhibitors in vitro and in vivo. A preclinical study evalu-
ating the inhibitory concentrations of selumetinib showed
strong sensitivity of BRAF mutant cell lines whereas about
60% of KRAS mutant cell lines were insensitive towards
selumetinib with EC50 concentrations often far above 1
μM [54]. Concentrations of higher than 1 μM are hardly
achieved in patients and cell lines are considered sensitive
towards inhibitors if the EC50 concentration is well below 1
μM; usually concentrations are within the nanomolar range
and BRAF mutant cell lines, for example, show sensitivit-
ies lower than 0.1 μM [24]. In a phase I study of trametin-
ib, three patients with NSCLC responded to treatment [32].
Only one of the three was KRAS mutated and the two other
responders had EGFR mutation, whereas most nonrespon-
ders were KRAS mutated [32]. Thus, this study shows that
(1) clinical data correlate with in-vitro studies in cell lines
and (2) that KRAS mutations alone are a poor predict-
ive marker for single-agent therapy with MEK inhibitors.
However, a recent phase II study showed that the combin-
ation of selumetinib with docetaxel has promising efficacy
in second-line treatment for KRAS mutant NSCLC [55].
Although, treatment was not compared between KRAS
wildtype and KRAS mutant patients in this study, clinical
activity might be higher for KRAS mutant patients if res-
ults are compared with other phase II studies of selumetinib
in unselected patients [56]. Therefore, outcomes from the
phase III combination study of selumetinib and docetaxel
in KRAS mutant NSCLC patients are awaited. In con-
clusion, KRAS mutations have so far failed to prove a
powerful predictive marker for treatment with MEK inhib-
itors and KRAS mutations might require combination treat-
ments to result in clinical meaningful effects.
NRAS is a promising predictive marker
Interestingly, NRAS as a predictive target for MEK inhib-
itors is rarely studied. Although, a plethora of recent pre-
clinical data clearly shows that NRAS mutations predict
for sensitivity to MEK inhibitors in cell line studies, clin-
ical proof-of-concept data are rare. NRAS mutations were
detected in 2% of high-risk cutaneous T-cell lymphomas
(CTCL), and a CTCL cell line harbouring a NRAS Q61K
mutation was highly sensitive to three different MEK in-
hibitors at low nanomolar concentrations [56]. NRAS
mutations occur in 0.5–1% of NSCLC patients, mostly of
adenocarcinoma histology and five of six NRAS mutant
lung cancer cell lines were sensitive to the MEK inhibitors
selumetinib and trametinib [56]. NRAS is mutated in
15–25% of melanoma patients and NRAS mutant melan-
oma cell lines are very sensitive to MEK inhibitors [3, 59].
Since NRAS mutations are most abundant in melanoma,
the MEK inhibitor binimetinib (MEK162) is so far the sole
MEK inhibitor studied specifically in a selected NRAS
mutant patient population. In a phase I study with biliary
cancer and colorectal cancer patients, 1 complete response
and 1 partial response out of 26 patients were observed
[60]. Consequently, a phase II study investigated the effect
of binimetinib in NRAS and BRAF mutant melanoma pa-
tients. Objective responses were found in 6 out of 30 (20%)
patients with NRAS mutant melanoma and in 8 out of 41
(20%) with BRAF mutant melanoma [61]. Patients with
previous BRAF inhibitor treatment were allowed in this tri-
al, which may explain the lower response rates of 20%.
Nevertheless, this study clearly shows that NRAS can be
a predictive marker for MEK inhibitors in clinical therapy.
These encouraging data led to the initiation of a phase
III study of the MEK inhibitor binimetinib. This study is
called NEMO trial for “NRAS mElanoma and MEK in-
hibitOr” and compares binimetinib with dacarbazine in pa-
tients with metastatic NRAS mutant melanoma.
There have been fewer studies of MEK inhibitors in
haematological malignancies. In acute myeloid leukaemia
(AML), a phase II trial of selumetinib was performed in-
cluding 3 of 47 patients harbouring a NRAS mutation.
However, selumetinib resulted in only modest response, in-
dependent of the NRAS or KRAS mutation status [40].
This indicates that either more AML patients with NRAS
mutations have to be included in clinical trials or that the
potency of NRAS as a predictive marker is dependent on
tissue background and lineage.
Targeting mutant HRAS: preclinical and clinical data
Even though HRAS mutations can be found in a significant
number of cancers, including squamous cell cancer of the
lung (2.8%), head and neck cancer (3.9%) and bladder can-
cer (5.1%), little is known about targeting mutant HRAS
[62]. We have investigated several HRAS mutant cancer
cell lines and observed strong sensitivity to MEK inhibitors
in vitro and in vivo compared with HRAS wildtype cell
lines [63]. These data showed that, at least in a preclinical
setting, HRAS mutations predict sensitivity to MEK inhib-
itors.
Clinical characteristics and behaviour of HRAS mutant
cancer patients have been described rarely. One recent re-
port described an adenocarcinoma of the lung with HRAS
Q61L mutation associated with from rapid progression and
deterioration, suggesting that HRAS mutations in NSCLC
tumours could be fast growing and associated with poor
prognosis [64]. Interestingly, one phase I trial for the novel
MEK inhibitor RO5126766 reported a tumour patient with
HRAS mutation who had 20% tumour shrinkage due to
MEK inhibitor treatment [65]. This is the first hint that
HRAS mutant cancer patients might benefit clinically from
MEK inhibitor treatment.
Outlook to the future
Despite the high number of mutations found in the RAS
pathway only a few patients seem to be eligible for treat-
ment with specific RAF and MEK inhibitors. Whereas
BRAF mutations are a crucial predictive marker for treat-
ment with RAF and MEK inhibitors in melanoma patients,
the role of NRAS, KRAS and HRAS as markers has to be
further studied. However, striking activity has been demon-
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strated for MEK inhibitors in selected RAS mutant patient
populations and several phase II and phase III studies in
RAS mutant patients are currently ongoing. The activity of
MEK inhibitors might be further enhanced by combination
with other small molecule inhibitors (e.g., AKT inhibitors
and PI3K inhibitors) or classical cytotoxic agents. The res-
ults of ongoing trials are awaited with high interest.
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Figure 1
Schematic representation of the RAS signalling pathway. RAS activates both the MAPK and the PI3K/mTOR pathways downstream. Inhibitors
for both pathways are shown. Vemurafenib, dabrafenib and cobimetinib are approved in Switzerland, whereas others are mostly in early and
some in advanced clinical development.
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